Reply to: “Insights into Fracture Risk with Tenofovir and Entecavir: Evidence from Pharmacovigilance Data”

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-11-20 DOI:10.1016/j.jhep.2024.11.019

Jimmy Che-To Lai, Mary Yue Wang, Terry Cheuk-Fung Yip

{"title":"Reply to: “Insights into Fracture Risk with Tenofovir and Entecavir: Evidence from Pharmacovigilance Data”","authors":"Jimmy Che-To Lai, Mary Yue Wang, Terry Cheuk-Fung Yip","doi":"10.1016/j.jhep.2024.11.019","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions:</h2>All authors were responsible for the study concept, data acquisition and analysis, the integrity of the data and the accuracy of the data analysis, the drafting, and the critical revision of the manuscript for important intellectual content, and approved the final version of the article. Terry Yip is the submission’s guarantor of the article.</section></section><section><section><h2>Financial support:</h2>None</section></section><section><section><h2>Declaration of Competing Interest:</h2>Jimmy Lai has served as a speaker for Gilead Sciences and an advisory board committee for Gilead Sciences and Boehringer Ingelheim.Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences.Mary Wang declares that she has no competing interests.We extend our sincere gratitude to Ge <em>et al.</em> [1] for their valuable insights on our territory-wide cohort study, which involved patients identified from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.11.019","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Authors' contributions:

All authors were responsible for the study concept, data acquisition and analysis, the integrity of the data and the accuracy of the data analysis, the drafting, and the critical revision of the manuscript for important intellectual content, and approved the final version of the article. Terry Yip is the submission’s guarantor of the article.

Financial support:

None

Declaration of Competing Interest:

Jimmy Lai has served as a speaker for Gilead Sciences and an advisory board committee for Gilead Sciences and Boehringer Ingelheim.Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences.Mary Wang declares that she has no competing interests.We extend our sincere gratitude to Ge et al. [1] for their valuable insights on our territory-wide cohort study, which involved patients identified from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital

查看原文本刊更多论文

答复"透视替诺福韦和恩替卡韦的骨折风险：来自药物警戒数据的证据"

章节片段作者贡献：所有作者均对研究构思、数据采集和分析、数据的完整性和数据分析的准确性、稿件的起草和重要知识内容的批判性修改负责，并批准了文章的最终版本。财务支持：无竞争利益声明：Jimmy Lai曾担任吉利德科学公司的演讲人，以及吉利德科学公司和勃林格殷格翰公司的顾问委员会成员。我们衷心感谢 Ge 等人[1] 对我们的全港队列研究提出的宝贵意见，该研究涉及的患者是从医院临床数据分析和报告系统 (CDARS) 中识别出来的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.